PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 71 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2023. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $39,718,000 | +10.1% | 3,689,538 | +30.0% | 1.17% | +71.2% |
| Q2 2019 | $36,076,000 | -64.3% | 2,838,376 | +9.0% | 0.68% | -69.3% |
| Q1 2019 | $101,006,000 | +19.0% | 2,603,920 | +40.6% | 2.23% | +79.4% |
| Q3 2018 | $84,898,000 | -10.1% | 1,851,638 | +16.0% | 1.24% | -15.9% |
| Q2 2018 | $94,450,000 | -31.7% | 1,596,783 | -21.4% | 1.48% | -47.4% |
| Q1 2018 | $138,320,000 | -23.2% | 2,032,619 | +11.6% | 2.81% | -34.2% |
| Q4 2017 | $180,085,000 | +9.8% | 1,821,800 | +33.0% | 4.27% | +32.5% |
| Q3 2017 | $164,007,000 | -5.8% | 1,369,579 | -31.2% | 3.22% | -31.3% |
| Q2 2017 | $174,036,000 | +339.1% | 1,991,258 | +86.9% | 4.69% | +372.7% |
| Q1 2017 | $39,631,000 | +12.9% | 1,065,356 | -6.8% | 0.99% | +0.3% |
| Q4 2016 | $35,111,000 | -19.9% | 1,143,688 | -22.3% | 0.99% | -25.2% |
| Q2 2016 | $43,847,000 | +522.7% | 1,471,879 | +598.0% | 1.32% | +467.8% |
| Q1 2013 | $7,041,000 | – | 210,883 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 2,536,156 | $21,405,000 | 2.24% |
| Palo Alto Investors LP | 1,396,163 | $11,784,000 | 0.99% |
| Camber Capital Management LP | 1,950,000 | $16,458,000 | 0.98% |
| TANG CAPITAL MANAGEMENT LLC | 800,000 | $6,752,000 | 0.95% |
| Capital Impact Advisors, LLC | 147,303 | $1,243,000 | 0.52% |
| Sofinnova Investments, Inc. | 638,026 | $5,385,000 | 0.50% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 963,212 | $8,130,000 | 0.26% |
| RICE HALL JAMES & ASSOCIATES, LLC | 466,482 | $3,937,000 | 0.22% |
| PDT Partners, LLC | 204,238 | $1,724,000 | 0.14% |
| Eversept Partners, LP | 58,251 | $491,638 | 0.12% |